ATTENTION! This webpage is hosted on EthicsPoint's secure servers and is not part of the Sun Pharma website or intranet.
This Disclosure Program is to provide a channel for those who wish to disclose to the CDRO any issues or questions associated with policies, conduct, practices, or procedures believed to be a potential violation of the U.S. Federal Food, Drug, and Cosmetic Act related to Legacy Ranbaxy Facilities. Legacy Ranbaxy Facilities include the following:
- Ranbaxy Laboratories, Ltd., Sirmour District, Himachal Pradesh, India (known as Paonta Sahib).
- Ranbaxy Laboratories, Ltd., Industrial Area-3, Dewas, India.
- Ohm Laboratories, 14 Terminal Road, New Brunswick, NJ.
- Ohm Laboratories, Van Dyke Ave., New Brunswick, NJ.
- Ohm Laboratories, 1385 Livingston Ave. North Brunswick, NJ.
- Ranbaxy Inc., 600 College Road East, Princeton, NJ.
- Ranbaxy Laboratories, Ltd., P.O. Rail Majra, Toansa, Dist. Nawanshahar, Punjab, India.
- Ranbaxy Laboratories, Ltd., Phase III Ind. Area, SAS Nagar and Unit III, A41, Phase VIIIA, Mohali, Punjab, India.
- Ranbaxy Laboratories, Ltd., Sector 18 Udyog Vihar Industrial Area (Gurgaon, India).
- Any other Legacy Ranbaxy Facility, which includes Ranbaxy Laboratories, Ltd., Ranbaxy Inc., and any subsidiaries of those companies as they existed at the time Ranbaxy was acquired by Sun Pharmaceuticals on March 24, 2015.